Media stories about Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been trending positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adaptimmune Therapeutics PLC earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0647381909906 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
ADAP has been the topic of several recent research reports. ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Leerink Swann restated an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Wednesday, July 12th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $10.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.58.
Adaptimmune Therapeutics PLC (NASDAQ ADAP) opened at 7.67 on Friday. The stock’s 50 day moving average is $8.04 and its 200-day moving average is $8.04. The firm’s market cap is $717.29 million. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) EPS for the quarter, hitting the consensus estimate of ($0.24). The business had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. On average, equities research analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Earning Favorable News Coverage, Report Finds” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/28/positive-news-coverage-somewhat-unlikely-to-impact-adaptimmune-therapeutics-plc-adap-stock-price.html.
About Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.